

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: GASCO ET AL-1 PCT (RCE)			SERIAL NO. 10/533,512	
(Modified) LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT: Maria Rosa GASCO ET AL				
				FILING DATE: May 2, 2005			GROUP: 1617	
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA	7,153,525	12/2006	Mumper et al.				
	AB	5,250,236	10/1993	Gasco, Maria R.				
	AC	6,720,008	04/2004	Allison, Stewart Dean				
	AD	5,962,016	10/1999	Willies et al.				
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AE	WO 02/076427	10/2002	International				
	AF	WO 2004/039351	05/2004	International				
	AG	WO 00/30620	06/2000	International				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	AL	Bhatt et al., "Lipid Technology- A Promising Drug Delivery System for Poorly Water Soluble Drugs," International Journal of Pharma. Research & Development - Online, ISSN 0974-9446, September 2010, Vol. 2, Issue 7, pgs. 1-11. (Attached to accompanying Response as Annex A)						
	AM	Goodman & Gilman's, "The Pharmacological Basis of Therapeutics," Ninth Edition, 1996, McGraw-Hill, pages 1625, 1630 and 1633. (Attached to accompanying Response as Annex B)						
	AN	emedicinehealth, "Normal-Tension Glaucoma," retrieved on January 21, 2011, one page. (Attached to accompanying Response as Annex C)						
	AO	Wikipedia, the free encyclopedia, "Glaucoma," retrieved on January 19, 2011, pages 1-11. (Attached to accompanying Response as Annex D)						
	AP	Viola et al., "Solid Lipid Nanoparticles Topically Administered in Rabbits as New Drug Delivery System: A Preliminary Study of Safety and Bioavailability," Abstract, ARVO 2009 Annual Meeting, Fort Lauderdale, 2009, pages 1-2. (Attached to accompanying Response as Annex E)						
	AQ	Franceschetti et al., "[Viral retinitis pigmentosa; relation between clinical picture and electroretinogram]," May-June, 1958; 135: 545-554, Abstract enclosed. (Attached to accompanying Response as Annex F)						
	AR	Cavalli et al., "Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair," International Journal of Pharmaceutics, 117 (1995) pages 243-246. (Attached to accompanying Response as Annex G)						
	AS	Strettoi et al., "Inhibition of ceramide biosynthesis preserves photoreceptor structure and function in a mouse model of retinitis pigmentosa," PNAS Early Edition, 2010, pages 1-6. (Attached to accompanying Response as Annex H)						
	AT	Strettoi et al., Supporting Information for the document [Strettoi et al., "Inhibition of ceramide biosynthesis preserves photoreceptor structure and function in a mouse model of retinitis pigmentosa," PNAS Early Edition, pages 1-6.], 2010, pages 1-4. (Attached to accompanying Response as Annex I)						
EXAMINER					DATE CONSIDERED			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: GASCO ET AL-1 PCT (RCE)			SERIAL NO. 10/533,512	
(Modified) LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT: Maria Rosa GASCO ET AL				
				FILING DATE: May 2, 2005			GROUP: 1617	
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	BA							
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BE							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	BH	Dinauer N. et al: "Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation," JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS, B.V. AMSTERDAM, NL, vol. 96, no. 3, 18 May 2004 (2004-05-18), pages 497-507.						
	BI	Zimmer A. et al. "Synthesis of cholesterol modified cationic lipids for liposomal drug delivery of antisense oligonucleotides," EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 47, no. 2, 1 March 1999 (1999-03-01), pages 175-178.						
	BJ	Chirila T.V. et al: "The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides," BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 23, no. 2, January 2002 (2002-01), pages 321-342.						
	BK	"Preclinical and Phase 1A Clinical Evaluation of an Anti-VEGF Pegylated Aptamer (EYE001) for the Treatment of Exudative Age-Related Macular Degeneration," Retina, Philadelphia, PA, US, vol. 22, no. 2, April 22 (2002-04), pages 143-152.						
	BL	Lambert G., Fattal E., Couvreur P., "Nanoparticulate systems for the delivery of antisense oligonucleotides," Advanced Drug Delivery Reviews (2001); 47(1): 99-112. (Abstract enclosed)						
	BM	Aukunuru JV, Ayalasomayajula SP, Kompella UB, "Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells," J. Pharm. Pharmacol. (2003), 55, 1199-1206. (Abstract enclosed)						
	BN	Surowiak P., "Evaluation of transfection effectiveness using fluorescein-labelled oligonucleotides and various liposomes," Folia Morphol (Warsz) (2003); 62(4): 397-9. (Abstract enclosed)						
	BO	Jurkiewicz P., Okruszek A., Hof M. Langner M., "Associating oligonucleotides with positively charged liposomes," Cellular & Molecular Biology Letter (2003); volume 8; pages 77-84.						
	BP	Wong F.M.P., MacAdam SA, Kim A, Oja C. Ramsay E.C., Bally M.B., "A lipid-based delivery system for antisense oligonucleotides derived from a hydrophobic complex," Journal of Drug Targeting 2002, volume 10, 615-623. (Abstract enclosed)						
EXAMINER				DATE CONSIDERED				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.